SLC5A2 and metabolic dysfunction-associated steatotic liver disease: There are also no studies assessing the effect on NAFLD patients liver histology of Sodium–Glucose Co-Transporter 2 (SGLT2) Inhibitors (canagliflozin or dapagliflozin), agents that lower renal glucose absorption.